Late Breaking Abstract - BIOMARKER ALBUMIN MODIFIED BY ISCHEMIA AS A PREDICTOR OF FUTURE CARDIOVASCULAR RISK IN PATIENTS WITH SLEEP APNEA SYNDROME AND TREATMENT WITH CPAP VS USUAL CARE TREATMENT

<bold>Introduction:</bold> The biomarker Ischemia Modified Albumin (IMA), accepted for the diagnosis of cardiac ischemia in adults, is considered a biomarker for direct measurement of oxidative stress, a common pathophysiological mechanism with OSA. <bold>Objetive:</bold> To assess the evolution of IMA, in terms of new cardiovascular events (CV mortality, admission for heart failure, coronary revascularization procedures, unstable angina) throughout the follow-up, depending on the baseline IMA values, severity of OSA and the treatment applied (CPAP vs conservative treatment). <bold>Methods:</bold> Nested study in the ISAAC project, a multicenter, open-label, parallel, prospective, randomized, controlled study (registration number: NCT 01335087) of patients with ACS and OSA. We included 925 patients who underwent cardiorespiratory polygraphy in the first 24-72 as well as a venous blood draw to determine IMA values. The patients were recruited consecutively and the group distribution (based on the apnea/hypopnea index [AHI]). Subsequently, patients with AHI ≥ 15 events/h were randomized to receive treatment with continuous positive airway pressure (CPAP) or conservative treatment. <bold>Conclusions:</bold> Patients with moderate-severe OSA, after being randomized to treatment with CPAP or conservative treatment, do not present a higher rate of new cardiovascular events (CV mortality, admission for CHF, coronary revascularization procedures, unstable angina) throughout follow-up, depending on high or low IMA values.